We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Molecule Shows Promise Against Atherothrombosis

By Biotechdaily staff writers
Posted on 17 Dec 2003
Preclinical results of a molecule designed to combat atherothrombotic disease show that in treated mice, cholesterol levels dropped immediately, atheroma plaque showed signs of regression, and weight gain slowed.

Called Nimoxine, the molecule belongs to a family of molecules identified for their ability to reduce cholesterol and triglyceride levels. More...
The molecule can be used to block the accumulation of lipids and macrophages that are central to the growth of vascular lesions in patients with atherothrombosis. Nimoxine is being developed by ClinicGenetics (Nimes, France), a biopharmaceutical company that is identifying and developing new targets and products for the treatment of cardiovascular disease.

"The excellent results obtained from these preclinical trials endorse our approach to finding valid treatments for atherothrombotic disease,” said Dr. Gerard Marguerie, vice president and CEO of CliniGenetics. Instead of focusing on the two traditional therapeutic pathways, statins or antithrombotic therapy, the company has identified a third pathway, "stabilization therapy,” designed for patients who cannot tolerate existing therapies or for whom these treatments prove of limited efficacy.




Related Links:
CliniGenetics

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Repetitive Pipette
VWR® Stepper Pro
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Photo courtesy of Adobe Stock

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.